2Zamboni M, Mazzali G. Obesity in the elderly: an emerging healthissue[J]. Int J Obes(Lond), 2012,36: 1151-1152.
3Porirer P, Cornier MA, Mazzone T, et al. Bariatic surgery andcardiovascular risk factors: a scientific statement from the AmericanHeart Association [J]. Circulation, 2011, 123: 1683-1701.
4Ridderstrale M, Gudbjornsdottir S, Ellasson B, et al. SteeringCommittee of the Swedish Ntional Diabetes Register(NDR). Obesityand cardiovascular risk factors in type 2 diabetes: placebo results fromthe Swedish Ntional Diabetes Register[J]. J Intern Med, 2006,259(3):314-322.
5Henry RR, Clilton R, Garvey WT. New options for the treatment ofobesity and type 2 diabetes mellitus(narrative review)[J]. J DiabetesComplication, 2013,27: 508-518.
6Kodama S, Horikawa C, Fujihara K, et al. Quantitative relationshipbetween body weight gain in adulthood and incident type 2 diabetes: ameta-analysis[J]. Obesity reviews, 2014, 15, 202-214.
7Deurenberg P, Yap M, van Staveren WA. Body mass index and percentbody fat: a meta analysis among ethnic groups[J]. Int J Obes RelatMetab Disord, 1998,22: 1164-1171.
8Wang D, Li Y, Lee SG, et al. Ethnic differences in body composition andobesity related risk factors: study in Chinese and white males living inChina[J], PLoS One, 2011,6: el9835.
9Holman RR, Thome KI, Farmer AJ, et al. 4-T study group. Addition ofbiphasic, prandial, or basal insulin to oral therapy in type 2 diabetes [J].N Engl Med, 2007’ 375: 1716-1730.
10UK prospective Diabetes Study(UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared withconventional treatment and risk of complications in patients with type 2diabetes(UKPDS33) [J]. Lancet, 1998, 352: 837-853.
二级参考文献39
1WILD S, ROGLIC G, GREEN A, et al. Global prevalence of diabetes:estimates for the year2000 and projections for 2030 [J]. Diabetes Care, 2004,27 ( 10 ) : 1047 - 1053.
2BUSE JB, KLONOFF DC, NIELSEN LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic bin-markers in patients with type 2 diabetes: an interim analysis of data from the open-label uncontrolled extension of three double-blind, placebo-controlled trials [J]. Clin Ther, 2007,29 (1): 139-153.
3KIM D, MACCONELL L, ZHUANG D, et al. Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjeets with type 2 diabetes [ J ]. Diabetes Care, 2007,30 ( 6 ) : 1487 - 1493.
4VINEET SH, REED JR, BERGMAN A J, et al. Metabolism and excretion of the DPP- inhibilor [ 14C ] sitigliptin in humans[ J]. Drug Metab Dispos,2007 ,35 ( 4 ) :533 -538.
5ASCHNER P, KIPNES MS, LUNCEFORD JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glyeemic control in patients with type 2 diabetes [J]. Diabetes Care,2006,29 (12) :2632 - 2637.
6BERNARD C, AVRAHAM K, Ji Liu, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [ J ] . Diabetes Care, 2006,29 (12) :2638 -2643.
7FDA Approves JANUMET^TM- DPP-4 inhibitor and metformin in a single tablet [EB/OL] http://www, diabetesincontrol, com/resuits, php? storyartiele =4881,2007 -06 - 12/2009 -05 - 16.
8PRETLEY RE, JAUFFRET KS, GALLBREATH E, et al. Twelveweek monotherapy with the DPP-4 inbibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [J]. Horm Metab Res, 2006,38(6) : 423 -428.
9LIST JF, WOO V, MORALES E. et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes[J]. Diabetes Care ,2009,32(4) :650 - 657.
10JABBOUR SA, GOLDSTEIN BJ. Sodium glucose co-transporter 2 inhibitors : blocking renal tuber reabsorption of glucose to improve glyceamic control in patientd with diabetes [J]. Int J Clin Proct,2008,62(8) :1279 - 1284.
